Figure 2.

(a) Percentage of timed-walk responders in placebo- and dalfampridine-treated patients. (b) Percentage change from baseline walking speed at each visit following randomization, by responder analysis group. The dalfampridine-treated timed-walk responder showed sustained improvement during treatment that was completely reversed at the 2-week follow-up visit. The dalfampridine-treated timed-walk nonresponder showed a smaller increase, similar to that seen in the placebo-treated group. (Adapted with permission from Goodman et al. [2010].) BID, twice daily; CI, confidence interval.